Hugh A. D'Andrade
The information listed below is current as of the date the transcript was finalized.
Abstract of Interview
Hugh A. D’Andrade begins the interview with a brief discussion of his education and early career. D’Andrade began his career in corporate law as General Attorney for the Ciba-Geigy Corporation in 1968. By 1977, he had risen through the ranks to become Vice President of Administration and Counsel of the Pharmaceuticals Division. In 1981, he joined Schering-Plough Corporation as Senior Vice-President of Administration. During D’Andrade’s first years with Schering, the company worked with Cetus Corporation on antibiotic screening, and also worked with Biogen on interferon and erythropoietin. D’Andrade served as Schering’s representative on Biogen’s board for six years, where he worked closely with Charles Weissmann, Walter Gilbert, Bernard Mach, Philip Sharp, and Walter Fiers. D’Andrade worked on the development side of the interferon project and was instrumental in patent negotiations with Roche. D’Andrade discusses the presence of biotechnology in New Jersey and its relationship to other biotechnology organizations across the country. He concludes the interview with a discussion on the acquisition of DNAX, and his involvement with Biotechnology Industry Organization (BIO) and the Industrial Biotechnology Association (IBA).
|1964||Columbia University Law School||LL B|
New Jersey Supreme Court
Toner, Crowley, Woelper, & Vanderbilt
Table of Contents
Growing up in Metuchen, New Jersey. Attending college and law school. Working for New Jersey Supreme Court Justice. Moving to private firm. Beginning career with Ciba-Geigy. Leaving Ciba-Geigy for Schering Plough. Schering's relationship with Cetus and Biogen. Moshe Alafi and Robert Luciano.
Biogen's Board. Working with Philip Sharp, Walter Gilbert, Bernard Mach, Walter Fiers, Jeremy Knowles, and Charles Weissmann. Erythropoietin and interferon research.
Working on interferon development. Obtaining patents. Weissmann patent. Biotechnology's presence in United States. Research of Walter Gilbert. Enthusiasm of scientists.
Success of relationship with DNAX. Research on therapeutic proteins. Interleukin-10. Emergence of biotechnology.
Relationship with Biotechnology Industry Organization (BIO) and the Industrial Biotechnology Association (IBA). Carl Feldbaum. Future of biotechnology.
About the Interviewer
Sally Smith Hughes graduated from the University of California, Berkeley, in 1963 with an A.B. in zoology. She received her M.A. in Anatomy from the University of California, San Francisco, in 1966. In 1972, she earned her Ph.D. in the history of science and medicine from the Royal Postgraduate Medical School, University of London. She served as postgraduate research histologist with the Cardiovascular Research Institute at the University of California, San Francisco from 1966–1969, and as science historian for the History of Science and Technology program at the Bancroft Library from 1978–1980. Dr. Hughes was the Othmer Fellow at the Chemical Heritage Foundation in 1997. She is presently research historian and principal editor on medical and scientific topics for the Regional Oral History Office, University of California, Berkeley. She is author of The Virus: A History of the Concept, and is currently interviewing and writing in the fields of AIDS and molecular biology and biotechnology.
Leo Slater was the 2001–2002 John C. Haas Fellow and a senior research historian at the Chemical Heritage Foundation in Philadelphia, where he also served as Director of Historical Services from 1997 to 2000. A former research chemist at the Schering-Plough Research Institute, he received his doctorate in History from Princeton University in 1997.